Healthcare / BiotechnologyNasdaqGM
$6.42
-0.50 (-7.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-60.4M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$428M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.5%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-74.9M · FCF $-60.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | — | — | $80.0M | $2.8M | $6.3M | — | — | — | — |
| Net Income | $-74.9M | $-74.9M | $-9.7M | $-97.3M | $-109.9M | $-80.8M | $-70.8M | $-82.7M | $-32.6M |
| EBITDA | $-83.4M | $-83.4M | $-18.2M | $-108.5M | $-109.7M | — | — | — | — |
| EPS | -1.18 | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 | — | — |
| Operating Margin | — | — | -24.8% | -3945.2% | -1768.1% | — | — | — | — |
| Net Margin | — | — | -12.2% | -3470.1% | -1732.4% | — | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.05 | 0.07 | — | — | — | — |
| Current Ratio | 34.33 | 34.33 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-60.4M | $-60.4M | $-2.5M | $-91.5M | $-99.0M | $-80.2M | $-55.0M | $-40.3M | $-31.5M |
| Returns | |||||||||
| ROE | -21.5% | -21.5% | -4.0% | -41.4% | -55.2% | -38.2% | -74.4% | -94.9% | 51.2% |
| Valuation | |||||||||
| P/B | 1.17 | 1.17 | 1.30 | 1.96 | 2.11 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | — | — | 2752.0% | -55.8% | — | — | — | — | — |
| EPS Growth | -637.5% | -637.5% | 89.9% | 34.8% | — | 17.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -1.18
Residual
-6.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.